Upadacitinib was associated with higher percentages of remission and endoscopic response regardless of previous failure of biologic therapy. This paper reports the Phase 3 efficacy and safety results of upadacitinib in patients with moderate-to-severe Crohn’s disease.

Significantly more patients receiving upadacitinib 45mg versus placebo achieved the co-primary endpoints at Week 12, including clinical remission and endoscopic response.